<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1433">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05374278</url>
  </required_header>
  <id_info>
    <org_study_id>13180640</org_study_id>
    <nct_id>NCT05374278</nct_id>
  </id_info>
  <brief_title>First-in-human Evaluation of EAAT2 PET Tracer in Healthy and Alzheimer's Diseased Brain</brief_title>
  <official_title>First-in-human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Healthy and Alzheimer's Diseased Brain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David Wilson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rio pharmaceuticals Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first in human study that will assess the safety and diagnostic performance of&#xD;
      [18F]RP-115 (fluorine-18 labeled RP115), a positron emission tomography (PET) agent. This&#xD;
      agent has the potential to identify the early changes that occur in the brains of patients&#xD;
      with Alzheimer disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Alzheimer's disease (AD) is the leading cause of dementia and represent a growing public&#xD;
      health concern with tremendous impact on patients and their families. Early diagnosis of AD&#xD;
      is essential. This study aims to develop a novel radiotracer to fill this unmet need. The&#xD;
      excitatory amino acid transporter 2 (EAAT2) is the main transporter for glutamate which is&#xD;
      primarily located on the astrocytes and is significantly down-regulated in select cerebral&#xD;
      regions of AD brain.&#xD;
&#xD;
      The goal of this study is to test the EAAT2 targeted positron emitting agent, [18F]Fluoro-&#xD;
      fluorenylasparaginate methyl ester ([18F]RP-115), to evaluate both safety as well as the&#xD;
      early changes in astrocytes in healthy control versus cognitively impaired Alzheimer patients&#xD;
      by quantitative PET imaging of EAAT2.&#xD;
&#xD;
      This is a single-center, non-blinded, pilot study. Enrollment of 68 subjects is anticipated.&#xD;
      Healthy volunteers will be recruited to determine normal biodistribution of the radiotracer.&#xD;
      Alzheimer patients and age-matched controls will be recruited in order to determine the&#xD;
      tracer performance. The primary endpoint relates to the safety of the [18F]RP-115 scan. The&#xD;
      secondary endpoint relates to acquisition, processing, and comparison of [18F]RP-115 PET data&#xD;
      in normal and Alzheimer's diseased brains. The project will be monitored and evaluated in&#xD;
      accordance with the principles of Good Clinical Practice (GCP).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 2, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of Administered dose</measure>
    <time_frame>A year</time_frame>
    <description>Each study participant will undergo a physical examination, vital signs, and ECGs prior to and after the scan and will also be monitored during the scan for adverse events. Additionally, a follow-up with the subject will be conducted 24-48 hours after [18F]RP-115 administration.&#xD;
Outcome Measure: Any adverse events will be recorded and graded according to Common Terminology Criteria for Adverse Events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dosimetry of [18F]RP-115</measure>
    <time_frame>A year</time_frame>
    <description>Whole-body PET/MRI scan will be conducted immediately after an [18F]RP-115 injection and last about 3.5 hours (including breaks) in 8 healthy volunteers (male and female). Equivalent organ radiation doses will be calculated in selected organs using the dynamic PET/MRI data in order to calculate the dosimetry of the tracer.&#xD;
Outcome Measure: Radiation exposure per organ as milliSievert/kg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biodistribution of [18F]RP-115</measure>
    <time_frame>A year</time_frame>
    <description>Whole-body PET/MRI scan will be conducted immediately after an [18F]RP-115 injection and last about 3.5 hours (including breaks) in 8 healthy volunteers (male and female). Percent injected activity (%IA) will be calculated in selected organs using the dynamic PET/MRI data in order to calculate the biodistribution of the tracer.&#xD;
Outcome Measure: Percent injected activity (%Injected radioactivity) in selected organs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>[18F]RP-115 diagnostic performance</measure>
    <time_frame>Three years</time_frame>
    <description>Sixty (60) subjects (subjects with Alzheimer disease and healthy age-matched controls) will undergo a brain PET/MRI scan that will be start 30-90 minutes after an [18F]RP-115 injection and will last about 60-90 minutes. In selected subjects, blood sample collection via arterial catheter will be performed. Significant changes in the [18F]RP-115 cerebral tracer binding parameters will be used in order to identify the primary affected regions in patients with Alzheimer disease compared to healthy age-matched controls.&#xD;
Outcome Measure: Radioactivity distribution volume in select organs, mCi/L</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Cohort 1 - dosimetry of [18F]RP-115 in healthy volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Establish [18F]RP-115 safety in the clinic with male and female PET imaging.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 - [18F]RP-115 in patients with Alzheimer disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Comparison of [18F]RP-115 PET binding between AD patients and age-matched cognitively normal controls</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 - [18F]RP-115 in age-matched controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Comparison of [18F]RP-115 PET binding between AD patients and age-matched cognitively normal controls</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F]RP-115 PET/MRI</intervention_name>
    <description>An I.V. bolus injection of 5-10 millicurie (mCi) [18F]RP-115 will be administered, followed by a PET/MRI scan</description>
    <arm_group_label>Cohort 1 - dosimetry of [18F]RP-115 in healthy volunteers</arm_group_label>
    <arm_group_label>Cohort 2 - [18F]RP-115 in age-matched controls</arm_group_label>
    <arm_group_label>Cohort 2 - [18F]RP-115 in patients with Alzheimer disease</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 40-75 years old&#xD;
&#xD;
          2. BMI age-suitable&#xD;
&#xD;
          3. Ability to provide written informed consent and willing to comply with protocol&#xD;
             requirements, or has a legal authorized representative/guardian who provides surrogate&#xD;
             informed consent.&#xD;
&#xD;
          4. No apparent physical disorder.&#xD;
&#xD;
          5. Radial, ulnar or brachial artery suitable for catheterization.&#xD;
&#xD;
          6. Non- smoker, and not taking over the counter nicotine cessation- to limit peripheral&#xD;
             metabolism events&#xD;
&#xD;
          7. Devoid of central nervous system prescription drugs for three weeks- to limit&#xD;
             peripheral metabolism events.&#xD;
&#xD;
             For Cohort 2 part B only:&#xD;
&#xD;
          8. Must have a study partner (informant) who spends a minimum average of 5 hours per week&#xD;
             with the participant (e.g. family member, significant other, friend, caregiver), is&#xD;
             generally aware of the participant's daily activities, can provide information about&#xD;
             the participant's cognitive and functional performance&#xD;
&#xD;
          9. Recent (within 6 mo.) mini mental examination clinical scores.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unable to provide written informed consent and unwilling to comply with protocol&#xD;
             requirements, or does not have a legal authorized representative/guardian who can&#xD;
             provide surrogate informed consent.&#xD;
&#xD;
          2. Inadequate arterial access.&#xD;
&#xD;
          3. Receipt of radioisotope &lt; 5 half-lives within [18F]RP-115 imaging- as to not confound&#xD;
             any scans with radiation background for previous scanning, and unsuitable organ&#xD;
             dosimetry thresholds from previous (&gt; two weeks) PET scans.&#xD;
&#xD;
          4. The performed [18F]RP-115 scan(s) must not represent &gt; 3 PET studies total within one&#xD;
             year.&#xD;
&#xD;
          5. Contra-indication to magnetic resonance, including permanent pacemaker, implantable&#xD;
             metallic device, etc.; or severe claustrophobia.&#xD;
&#xD;
          6. Participants who are pregnant (female patients of childbearing age will be tested&#xD;
             prior to injection of tracer- positive test excludes from the study)&#xD;
&#xD;
          7. Participants who are breast-feeding.&#xD;
&#xD;
          8. Have a medical condition or other circumstances that in the opinion of the project&#xD;
             physicians would significantly decrease chances of obtaining reliable data, achieving&#xD;
             the study objective or completing the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Wilson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Wilson, MD, PhD</last_name>
    <phone>415-514-6229</phone>
    <email>david.m.wilson@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Henry Vanbrocklin, PhD</last_name>
    <phone>415-353-4569</phone>
    <email>henry.vanbrocklin@ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>China Basin, UCSF</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Wilson, MD, PhD</last_name>
      <email>david.m.wilson@ucsf.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Snyder HM, Sperling R; Contributors. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018 Apr;14(4):535-562. doi: 10.1016/j.jalz.2018.02.018. Review.</citation>
    <PMID>29653606</PMID>
  </reference>
  <reference>
    <citation>Boche D, Gerhard A, Rodriguez-Vieitez E; MINC Faculty. Prospects and challenges of imaging neuroinflammation beyond TSPO in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2019 Dec;46(13):2831-2847. doi: 10.1007/s00259-019-04462-w. Epub 2019 Aug 8. Review.</citation>
    <PMID>31396666</PMID>
  </reference>
  <reference>
    <citation>Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, Holden J, Houle S, Huang SC, Ichise M, Iida H, Ito H, Kimura Y, Koeppe RA, Knudsen GM, Knuuti J, Lammertsma AA, Laruelle M, Logan J, Maguire RP, Mintun MA, Morris ED, Parsey R, Price JC, Slifstein M, Sossi V, Suhara T, Votaw JR, Wong DF, Carson RE. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007 Sep;27(9):1533-9. Epub 2007 May 9. Review.</citation>
    <PMID>17519979</PMID>
  </reference>
  <reference>
    <citation>Rice L, Bisdas S. The diagnostic value of FDG and amyloid PET in Alzheimer's disease-A systematic review. Eur J Radiol. 2017 Sep;94:16-24. doi: 10.1016/j.ejrad.2017.07.014. Epub 2017 Jul 20. Review.</citation>
    <PMID>28941755</PMID>
  </reference>
  <reference>
    <citation>Rodriguez-Vieitez E, Carter SF, Chiotis K, Saint-Aubert L, Leuzy A, Schöll M, Almkvist O, Wall A, Långström B, Nordberg A. Comparison of Early-Phase 11C-Deuterium-l-Deprenyl and 11C-Pittsburgh Compound B PET for Assessing Brain Perfusion in Alzheimer Disease. J Nucl Med. 2016 Jul;57(7):1071-7. doi: 10.2967/jnumed.115.168732. Epub 2016 Feb 16.</citation>
    <PMID>26912447</PMID>
  </reference>
  <reference>
    <citation>Arakawa R, Stenkrona P, Takano A, Nag S, Maior RS, Halldin C. Test-retest reproducibility of [(11)C]-L-deprenyl-D(2) binding to MAO-B in the human brain. EJNMMI Res. 2017 Dec;7(1):54. doi: 10.1186/s13550-017-0301-4. Epub 2017 Jun 20.</citation>
    <PMID>28634836</PMID>
  </reference>
  <reference>
    <citation>Cowburn R, Hardy J, Roberts P, Briggs R. Presynaptic and postsynaptic glutamatergic function in Alzheimer's disease. Neurosci Lett. 1988 Mar 21;86(1):109-13.</citation>
    <PMID>2896322</PMID>
  </reference>
  <reference>
    <citation>Scott HL, Tannenberg AE, Dodd PR. Variant forms of neuronal glutamate transporter sites in Alzheimer's disease cerebral cortex. J Neurochem. 1995 May;64(5):2193-202.</citation>
    <PMID>7722505</PMID>
  </reference>
  <reference>
    <citation>Hoshi A, Tsunoda A, Yamamoto T, Tada M, Kakita A, Ugawa Y. Altered expression of glutamate transporter-1 and water channel protein aquaporin-4 in human temporal cortex with Alzheimer's disease. Neuropathol Appl Neurobiol. 2018 Oct;44(6):628-638. doi: 10.1111/nan.12475. Epub 2018 Mar 4.</citation>
    <PMID>29405337</PMID>
  </reference>
  <reference>
    <citation>Li S, Mallory M, Alford M, Tanaka S, Masliah E. Glutamate transporter alterations in Alzheimer disease are possibly associated with abnormal APP expression. J Neuropathol Exp Neurol. 1997 Aug;56(8):901-11.</citation>
    <PMID>9258260</PMID>
  </reference>
  <verification_date>May 2022</verification_date>
  <study_first_submitted>December 24, 2021</study_first_submitted>
  <study_first_submitted_qc>May 9, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2022</study_first_posted>
  <last_update_submitted>May 9, 2022</last_update_submitted>
  <last_update_submitted_qc>May 9, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>David Wilson</investigator_full_name>
    <investigator_title>Professor, Radiology</investigator_title>
  </responsible_party>
  <keyword>Alzheimer Disease</keyword>
  <keyword>Nuclear medicine</keyword>
  <keyword>Positron emission tomography</keyword>
  <keyword>Magnetic resonance imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All of the individuals participants data collected during the trial, after de-identification.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Immediately following publication. No end date.</ipd_time_frame>
    <ipd_access_criteria>Anyone who wishes to access the data</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 8, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/78/NCT05374278/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

